UnitedHealth Is the Worst Dow Jones Stock Thursday. Here's Why
UnitedHealth is putting pressure on the 30-stock index Thursday after the insurance giant reported a rare revenue miss. This is what you need to know.


UnitedHealth Group (UNH) is the worst Dow Jones stock Thursday, putting pressure on the price-weighted index, after the health insurance company reported mixed results for its fourth quarter.
In the three months ending December 31, UnitedHealth's revenue increased 6.8% year over year to $100.8 billion, thanks in part to a 4.4% rise in premiums to $76.5 billion. Its earnings per share (EPS) were up 10.6% from the year-ago period to $6.81.
"The people of UnitedHealth Group remain focused on making high-quality, affordable healthcare more available to more people while making the health system easier to navigate for patients and providers, positioning us well for growth in 2025," said UnitedHealth CEO Andrew Witty in a statement.

Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
While the company's earnings topped the $6.72 per share that Wall Street was anticipating, UNH's revenue fell short of the $101.8 billion analysts called for, according to CNBC. This marks the first top-line miss for UnitedHealth since Q2 2020. Revenue from premiums also came in below expectations of $78.1 billion.
Additionally, UnitedHealth reaffirmed the 2025 outlook it provided last month, which calls for revenue in the range of $450 billion to $455 billion and earnings per share between $29.50 to $30.
Is UnitedHealth stock a buy, sell or hold?
UnitedHealth has underperformed the broad market over the past 12 months, up 6% on a total return basis (price change plus dividends) vs the S&P 500's 26% gain. But Wall Street remains overwhelmingly bullish on the blue chip stock.
According to S&P Global Market Intelligence, the average analyst target price for UNH stock is $639.16, representing implied upside of more than 20% to current levels. Additionally, the consensus recommendation is a Strong Buy.
Financial services firm Oppenheimer has an Outperform rating (equivalent to a Buy) on UNH stock with a $640 price target.
"We believe UNH is well positioned by virtue of its diversification, strong track record, elite management team, and exposure to certain higher growth businesses," wrote Oppenheimer analyst Michael Wiederhorn in a December 5 note.
He adds that UnitedHealth's Optum business "is a nice complement to its core managed care operations and continues to account for a large share of earnings" and its "vertical integration strategy strengthens the company's competitive positioning across many areas of the healthcare landscape."
Related Content
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.

Joey Solitro is a freelance financial journalist at Kiplinger with more than a decade of experience. A longtime equity analyst, Joey has covered a range of industries for media outlets including The Motley Fool, Seeking Alpha, Market Realist, and TipRanks. Joey holds a bachelor's degree in business administration.
-
Five Tips For Estate Planning in 2025
We're almost halfway through the year. Is your estate in order? If not, here are some tips to get it done in 2025.
By Donna Fuscaldo
-
Is it Still a Good Idea to Give Savings Bonds as Gifts?
Kiplinger editor explores if it's still a good idea to get savings bonds as gifts for children, looking at their returns and usability.
By Alexandra Svokos
-
Is Giving Savings Bonds as Gifts Still a Good Idea?
Kiplinger editor explores if it's still a good idea to get savings bonds as gifts for children, looking at their returns and usability.
By Alexandra Svokos
-
Don't Veer Off Course at the First Sign of a Squall in the Markets
When markets go nuts and investor sentiment drops, you can keep your sanity by trusting in and sticking with your long-term plan.
By James Martielli, CFA®, CAIA®
-
How Business Owners Can Prepare for a Terminal Diagnosis
The most important thing is readiness, whether the owner faces a life-changing diagnosis or an employee does.
By H. Dennis Beaver, Esq.
-
Advisers, Take Note: How 2025 Social Security Changes May Impact Your Clients
What financial advisers might need to know to help their clients navigate Social Security in 2025.
By Jake Klima
-
Stock Market Today: Have We Seen the Bottom for Stocks?
Solid first-quarter earnings suggest fundamentals remain solid, and recent price action is encouraging too.
By David Dittman
-
Social Security Is Taxable, But There Are Workarounds
If you're strategic about your retirement account withdrawals, you can potentially minimize the taxes you'll pay on your Social Security benefits.
By Todd Talbot, CFP®, NSSA, CTS™
-
Serious Medical Diagnosis? Four Financial Steps to Take
A serious medical diagnosis calls for updates of your financial, health care and estate plans as well as open conversations with those who'll fulfill your wishes.
By Thomas C. West, CLU®, ChFC®, AIF®
-
What Wall Street's CEOs Are Saying About Trump's Tariffs
We're in the thick of earnings season and corporate America has plenty to say about the Trump administration's trade policy.
By Karee Venema